Prognostic Significance of CD109 Expression in Patients with Ovarian Epithelial Cancer
0
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Background: Ovarian epithelial cancer (OEC) is the second-most common gynecologic malignancy. CD109 expression is elevated in human tumor cell lines and carcinomas. A previous study showed that CD109 expression is elevated in human tumor cell lines and CD109 plays a role in cancer progression. Therefore, this study aimed to determine whether CD109 is expressed in OEC and can be useful in predicting the prognosis. Methods: Immunohistochemical staining for CD109 and reverse transcription-quantitative polymerase chain reaction was performed. Then we compared CD109 expression and chemoresistance, overall survival, and recurrence-free survival of OEC patients. Chemoresistance was evaluated by dividing into good-response group and poor-response group by the time to recurrence after chemotherapy. Results: CD109 expression was associated with overall survival (p = .020), but not recurrence-free survival (p = .290). CD109 expression was not an independent risk factor for overall survival due to its reliability (hazard ratio, 1.58; p = .160; 95% confidence interval, 0.82 to 3.05), although we found that CD109 positivity was related to chemoresistance. The poor-response group showed higher rates of CD109 expression than the good-response group (93.8% vs 66.7%, p = .047). Also, the CD109 mRNA expression level was 2.88 times higher in the poor-response group as compared to the good-response group (p = .001). Conclusions: Examining the CD109 expression in patients with OEC may be helpful in predicting survival and chemotherapeutic effect.
Abstract
Background: Ovarian epithelial cancer (OEC) is the second-most common gynecologic malignancy. CD109 expression is elevated in human tumor cell lines and carcinomas. A previous study showed that CD109 expression is elevated in human tumor cell lines and CD109 plays a role in cancer progression. Therefore, this study aimed to determine whether CD109 is expressed in OEC and can be useful in predicting the prognosis. Methods: Immunohistochemical staining for CD109 and reverse transcription-quantitative polymerase chain reaction was performed. Then we compared CD109 expression and chemoresistance, overall survival, and recurrence-free survival of OEC patients. Chemoresistance was evaluated by dividing into good-response group and poor-response group by the time to recurrence after chemotherapy. Results: CD109 expression was associated with overall survival (p = .020), but not recurrence-free survival (p = .290). CD109 expression was not an independent risk factor for overall survival due to its reliability (hazard ratio, 1.58; p = .160; 95% confidence interval, 0.82 to 3.05), although we found that CD109 positivity was related to chemoresistance. The poor-response group showed higher rates of CD109 expression than the good-response group (93.8% vs 66.7%, p = .047). Also, the CD109 mRNA expression level was 2.88 times higher in the poor-response group as compared to the good-response group (p = .001). Conclusions: Examining the CD109 expression in patients with OEC may be helpful in predicting survival and chemotherapeutic effect.
참고문헌 (31)
- Montes AF, "Ovarian cancer: basic science perspective", pp.1~16 (2012), InTech
- Flam F, "Symptomatology of ovarian cancer", Eur J Obstet Gynecol Reprod Biol, 27, pp.53~57 (1988)
- Goff BA, "Ovarian carcinoma diagnosis", Cancer, 89, pp.2068~2075 (2000)
- Liu J, "New strategies in ovarian cancer : translating the molecular complexity of ovarian cancer into treatment advances", Clin Cancer Res, 20, pp.5150~5156 (2014)
- Hartmann LC, "Prognostic significance of p53 immunostaining in epithelial ovarian cancer", J Clin Oncol, 12, pp.64~69 (1994)
- Luo H, "The prognostic value of HER2in ovarian cancer : a meta-analysis of observational studies", PLoS One, 13, pp.e0191972~ (2018)
- Lin M, "Cell surface antigen CD109 is a novel member of the alpha(2)macroglobulin", C3, C4, C5 family of thioester-containing proteins, 2002, pp.99, 1683~1691
- Hasegawa M, "CD109, a new marker for myoepithelial cells of mammary, salivary, and lacrimal glands and prostate basal cells", Pathol Int, 57, pp.245~250 (2007)
- Leivonen SK, "Transforming growth factor-beta signaling in cancer invasion and metastasis", Int J Cancer, 121, pp.2119~2124 (2007)
- Zhang JM, "CD109 expression in squamous cell carcinoma of the uterine cervix", Pathol Int, 55, pp.165~169 (2005)
- Sato T, "High-level expression of CD109 is frequently detected in lung squamous cell carcinomas", Pathol Int, 57, pp.719~724 (2007)
- Dong F, "CD109 is a novel marker for squamous cell", adenosquamous carcinomas of the gallbladder, 2015, pp.10, 137~
- Ozbay PÖ, "Investigation of prognostic significance of CD109 expression in women with vulvar squamous cell carcinoma", Onco Targets Ther, 6, pp.621~627 (2013)
- Emori M, "High expression of CD109antigen regulates the phenotype of cancer stem-like cells", cancerinitiating cells in the novel epithelioid sarcoma cell line ESX and is related to poor prognosis of soft tissue sarcoma, 2013, pp.8, e84187~
- Emori M, "Prognostic impact of CD109expression in myxofibrosarcoma", J Surg Oncol, 111, pp.975~979 (2015)
- Kurman RJ, "WHO classification of tumours of female reproductive organs", International Agency for Research on Cancer, 11~40 (2014)
- Shimizu Y, "Toward the development of a universal grading system for ovarian epithelial carcinoma : testing of a proposed system in a series of 461 patients with uniform treatment and follow-up", Cancer, 82, pp.893~901 (1998)
- Pecorelli S, "FIGO staging of gynecologic cancer. 1994-1997 FIGO Committee on Gynecologic Oncology. International Federation of Gynecology and Obstetrics", Int J Gynaecol Obstet, 65, pp.243~249 (1999)
- Yuan JS, "Statistical analysis of realtime PCR data", BMC Bioinformatics, 7, pp.85~ (2006)
- Hashimoto M, "Expression of CD109in human cancer", Oncogene, 23, pp.3716~3720 (2004)
- Hagiwara S, "Up-regulation of CD109expression is associated with carcinogenesis of the squamous epithelium of the oral cavity", Cancer Sci, 99, pp.1916~1923 (2008)
- Hagiwara S, "Processing of CD109 by furin and its role in the regulation of TGF-beta signaling", Oncogene, 29, pp.2181~2191 (2010)
- Cuppini L, "Prognostic value of CD109+ circulating endothelial cells in recurrent glioblastomas treated with bevacizumab and irinotecan", PLoS One, 8, pp.e74345~ (2013)
- Hasegawa M, "CD109 expression in basal-like breast carcinoma", Pathol Int, 58, pp.288~294 (2008)
- Tao J, "CD109 is a potential target for triple-negative breast cancer", Tumour Biol, 35, pp.12083~12090 (2014)
- Mancuso P, "A subpopulation of circulating endothelial cells express CD109 and is enriched in the blood of cancer patients", PLoS One, 9, pp.e114713~ (2014)
- Tsai YL, "Endoplasmic reticulum stress activates SRC, relocating chaperones to the cell surface where GRP78", CD109 blocks TGF-beta signaling, 2018, pp.115, E4245~54
- Sunagawa M, "Suppression of skin tumorigenesis in CD109-deficient mice", Oncotarget, 7, pp.82836~82850 (2016)
- Bhola NE, "TGF-beta inhibition enhances chemotherapy action against triple-negative breast cancer", J Clin Invest, 123, pp.1348~1358 (2013)
- Oshimori N, "TGF-beta promotes heterogeneity and drug resistance in squamous cell carcinoma", Cell, 160, pp.963~976 (2015)
- De Vita A, "Myxofibrosarcoma primary cultures : molecular and pharmacological profile", Ther Adv Med Oncol, 9, pp.755~767 (2017)